Treatment of mantle cell lymphoma: current approach and future directions.
Although mantle cell lymphoma has been described as "moderately aggressive" it has become clear that it carries a worse long-term prognosis than other subtypes of non-Hodgkin's lymphoma. In recent years, this has prompted numerous clinical trials of novel and more aggressive therapies in hopes of impacting these poor outcomes. These include more intensive combination chemotherapy regimens, monoclonal antibody therapy in conjunction with other treatments or conjugated to radioactive isotopes, high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation, and newer targeted therapies based on increasing understanding of the molecular pathways of this malignancy.
Brody
Joshua
J
Department of Medicine, Division of Oncology, Stanford University Medical Center, Clinical Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.
Advani
Ranjana
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D003131:Combined Modality Therapy / Q000639:trends; D018380:Hematopoietic Stem Cell Transplantation / Q000639:trends; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy*; D019172:Transplantation Conditioning / Q000639:trends; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome